Summit Trail Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
Other funds holding GILD
VCM
VPM
Summit Trail Advisors's GILD Position: Q1 2026 in Review
Summit Trail Advisors increased its Gilead Sciences (GILD) stake by 22% in Q1 2026, buying an estimated $1.11M and bringing the position to 43,831 shares worth $6.11M. The position accounts for 0.09% of the portfolio, ranked #127.
Summit Trail Advisors first reported a position in GILD in Q4 2017 and has held it in 20 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Summit Trail Advisors held 43,831 shares of Gilead Sciences worth $6.11M as of Q1 2026.
- Summit Trail Advisors bought 7,917 Gilead Sciences shares in Q1 2026, an estimated $1.11M.
- Gilead Sciences made up 0.09% of Summit Trail Advisors's portfolio in Q1 2026, its #127 holding.
- Summit Trail Advisors first reported a position in Gilead Sciences in Q4 2017 and has held it in 20 quarters since.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.